Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes. by Gurudas, Sarega et al.
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:13654  | https://doi.org/10.1038/s41598-021-93096-w
www.nature.com/scientificreports
Development and validation 
of resource‑driven risk prediction 
models for incident chronic kidney 
disease in type 2 diabetes
Sarega Gurudas1,9, Manjula Nugawela1,9, A. Toby Prevost2, Thirunavukkarasu Sathish3, 
Rohini Mathur4, J. M. Rafferty5, Kevin Blighe1, Ramachandran Rajalakshmi6, 
Anjana R. Mohan6, Jebarani Saravanan6, Azeem Majeed7, Viswanthan Mohan6, 
David R. Owens5, John Robson4, Sobha Sivaprasad8* & the ORNATE India Study Group
Prediction models for population‑based screening need, for global usage, to be resource‑driven, 
involving predictors that are affordably resourced. Here, we report the development and validation 
of three resource‑driven risk models to identify people with type 2 diabetes (T2DM) at risk of stage 3 
CKD defined by a decline in estimated glomerular filtration rate (eGFR) to below 60 mL/min/1.73m2. 
The observational study cohort used for model development consisted of data from a primary care 
dataset of 20,510 multi‑ethnic individuals with T2DM from London, UK (2007–2018). Discrimination 
and calibration of the resulting prediction models developed using cox regression were assessed using 
the c‑statistic and calibration slope, respectively. Models were internally validated using tenfold cross‑
validation and externally validated on 13,346 primary care individuals from Wales, UK. The simplest 
model was simplified into a risk score to enable implementation in community‑based medicine. The 
derived full model included demographic, laboratory parameters, medication‑use, cardiovascular 
disease history (CVD) and sight threatening retinopathy status (STDR). Two less resource‑intense 
models were developed by excluding CVD and STDR in the second model and HbA1c and HDL in the 
third model. All three 5‑year risk models had good internal discrimination and calibration (optimism 
adjusted C‑statistics were each 0.85 and calibration slopes 0.999–1.002). In Wales, models achieved 
excellent discrimination(c‑statistics ranged 0.82–0.83). Calibration slopes at 5‑years suggested models 
over‑predicted risks, however were successfully updated to accommodate reduced incidence of stage 
3 CKD in Wales, which improved their alignment with the observed rates in Wales (E/O ratios near to 
1). The risk score demonstrated similar model performance compared to direct evaluation of the cox 
model. These resource‑driven risk prediction models may enable universal screening for Stage 3 CKD 
to enable targeted early optimisation of risk factors for CKD.
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The prevalence of type 2 diabetes (T2D) and its complications are increasing rapidly around the world and 
chronic kidney disease (CKD) is one of the major  complications1,2. In 2017, approximately 697 million people 
were reported to have reduced glomerular function worldwide, with 125 million being related to  T2D3. The 
Kidney Disease: Improving Global Outcomes (KDIGO) group have developed clinical practice guidelines for 
improving the diagnosis and treatment of patients with diabetes and CKD based on estimated glomerular filtra-
tion rate (eGFR) and  albuminuria4. Given the wide variability in the rate of decline of glomerular function in 
people with T2D, prediction of a decrease of eGFR from normal ranges to less than 60 mL/min/1.73m2 is espe-
cially  challenging5.The kidney failure risk equation is useful for predicting more severe disease in people with 
 CKD6,7. Early identification of high-risk group will allow more efficient use of available resources to implement 
prevention strategies to avoid or slow the rate of downward trajectory to end stage renal  disease8.
Moreover, CKD shares common risk factors with diabetic retinopathy (DR) and cardiovascular disease (CVD) 
and identifying these complications incur significant healthcare  costs9–14. Many low- and middle-income coun-
tries (LMIC) have limited laboratory facilities and clinical expertise to screen for these complications, where 
average spending on healthcare can range US$100-US$400 per capita per annum compared with US$2000 in 
high income  countries15,16. Therefore, prediction models that identify early CKD in T2D have multiple beneficial 
effects in preventing multiple morbidities. However, there is a paucity of resource-friendly CKD risk models 
containing predictors that do not require costly technical or laboratory expertise and resources (table S1) that 
can be easily applied in  LMICs17,18. In this manuscript we refer to the development of such predictor models as 
resource-driven models.
In this study, we considered these limiting factors and aimed to build resource-driven stage 3 CKD predictive 
models that could be applied globally and in resource-constrained environments.
Methods
The Moorfields Research Management Committee approved the use of these fully anonymised UK retrospec-
tive datasets for model development and validation (SIVS1057). Approval was also obtained from the Caldecott 
guardian of these anonymised datasets in Queen Mary University London (QMUL) and Secure Anonymised 
Information Linkage (SAIL) in Wales. This study was conducted in accordance with the Declaration of Hel-
sinki. Patient-level consent was not required as the study only used fully anonymised routinely collected data 
(SIVS1057, Moorfields Eye Hospital dated 14/04/2020).
Study cohorts. We used two observational study cohorts derived from primary care electronic health 
record data for development and validation. The development cohort was extracted from a fully anonymised 
primary care dataset consisting of 105,533 people with T2D of multi-ethnic origin registered with 134 gen-
eral practices (GP) in inner London(London cohort)19. Fully anonymised data from the SAIL  databank20,21 was 
used for external validation, consisting of 140,157 T2D participants registered with over 170 primary care-GP 
practices from Wales of predominately White ethnicity (Wales cohort). The T2D and coding standards of both 
cohorts were consistent with the Quality outcomes Framework (QOF)22.
Both study cohorts enabled entry of individuals into the cohort at any time during the 11-year period 
(2007–2017). Cohort entry date was defined as the latest of date of 18th birthday, study start (01/01/2007) or date 
of registration with the GP. Follow-up time ended at the earliest date of study end (31/12/2017), de-registration 
from the GP, death or onset of CKD. We defined study baseline as the first T2D read code (a hierarchical diction-
ary of medical nomenclature)23 between entry and exit dates. Participants with a code for stage 3 + CKD, code 
for dialysis or eGFR < 60 ml/min/1.73  m2 on or prior to baseline were excluded from the cohort.
Outcomes. The endpoint was defined as the latest of the first two eGFR readings below 60 mL/min/1.73m2 
taken at least 3 months apart. Participants were also identified through read codes for dialysis or stage 3 CKD 
 onwards19. Data collection extended a maximum of 11 years, but as baseline risk factor data may become less 
predictive with time, the study outcome was censored at 5 years. The eGFR in both datasets was measured using 
the 4-variable Modification of Diet in Renal Disease Study Eq. 24.
Candidate predictors. Candidate predictors were pre-identified from review of literature (Table S1) pri-
oritising variables that are commonly available in clinical practice and key confounders of CKD (age, sex and 
ethnicity). These variables included age at baseline, gender, duration of diabetes, ethnicity, HbA1c level, total 
cholesterol, HDL cholesterol, body mass index (BMI), albumin-creatinine ratio (ACR), eGFR, use of anti-hyper-
tensives (anti-HTs), use of insulin, presence of CVD and sight threatening diabetic retinopathy (STDR).
Sample size. The development and cohort consisted of 1,378 events allowing for a maximum of 68 param-
eters within guidelines for the 14 covariates considered, plus additional parameters for interactions, fractional 
polynomials or categorical  variables25–27. The external validation cohort had adequate sample size achieving 10 
events per parameter (656 events).
Development of models. Full model (model 1). We developed 5-year Cox proportional hazards mod-
els for predicting incident eGFR < 60 mL/min/1.73m2 using Stata version  1628. We used fractional polynomial 
terms to model non-linear relationships for the continuous variables where appropriate. All continuous vari-
ables were scaled and centred. eGFR was categorised (every 10 ml/min/1.73m2 interval) due to the recording 
of normal eGFR in electronic health record (EHR) data as eGFR > 90 mL/min/1.73m2. Albumin to Creatinine 
ratio (ACR) was also categorised representing the clinical categories of risk (no albuminuria, microalbuminuria 
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and macroalbuminuria). Two-way interactions between age with insulin use, as well as between ethnicity with 
BMI, HbA1c and insulin were tested. Interactions were introduced once the fractional polynomial terms of the 
main effects were established. The best subset of predictors were selected by performing backward elimination 
with a stay criterion set to 0.05. To obtain the baseline survival estimate for calculation of the predicted risks, the 
predicted probability of remaining event-free was evaluated on an individual with zero-valued covariates and a 
survival time closest to 5 years (this is the mean adjusted baseline risk due to mean centering).
Reduced model (model 2). A reduced model was derived by removing predictors that would require complex 
tests and expertise for diagnosis and therefore unlikely to be applied in countries where these tests are unafford-
able. Therefore, STDR and CVD were removed as predictors. We checked whether the previously insignificant 
predictors became significant to re-enter the model. This is the first of the simplified models.
Minimal‑resources model (model 3). We then derived the minimal-resources model to only include predictors 
that required simple, and affordable tests so that they can be applied in very resource-constrained countries. 
Laboratory tests eGFR and ACR were kept in all the models due to their importance in the diagnosis and man-
agement of CKD and to emphasise the importance of these routine tests that are relatively inexpensive. Other 
relatively less predictive and costly laboratory tests were removed (HbA1c and HDL). This is the final simplified 
model.
Sensitivity analyses. First, in order to assess the impact of missing data, new prediction models were 
developed to assess change in discrimination and calibration of models from the original complete-case analy-
sis. For this, we reduced the proportion of missing data in ACR by increasing the criteria for measurement of 
ACR to within 2-years prior to, or up to 6 months after baseline. Second, TRIPOD  guidelines29 recommend the 
assessment of model performance in key subgroups, so we assessed discrimination and calibration in different 
subgroups in the Wales cohort, including non-modifiable risk factors of age at baseline (< 65 vs >  = 65 years), 
duration of diabetes at baseline (0 vs > 0 years) and gender both in original models and re-calibrated models 
(re-calibrated baseline survival in the total cohort). Furthermore, predicted and re-calibrated risks were assessed 
against observed rates by eGFR categories.
Internal validation. Model discrimination on the study cohort was assessed using Harrell’s C-statistic30. In 
order to minimise the risk of overfitting bias, internal validation was assessed using tenfold cross-validation31–34. 
The model’s calibration slope was assessed by calculating β coefficient for the linear predictor(LP), which aver-
ages the calibration slope across all time points. To assess the separation in risk thresholds, 4 risk groups were 
determined using the 16th, 50th and 84th centiles of the LP as per Cox’s  method35,36. Visual separation of the risk 
groups was assessed using the Kaplan–Meier (KM) plot.
External validation. Model discrimination and calibration was assessed using Harrell’s C-statistic and the 
calibration slope, respectively. The LP was categorised using cut-points from model development and event rates 
were compared between cohorts within each respective risk group. The beta coefficient for the calibration slopes 
gives an impression of whether risks were over or under-predicted across all time-points, however in order to 
visualise the calibration slope at a single time point, observed and predicted risks were plotted after categorising 
risks at 5-years into deciles. Sparse (fewer than 5 events) deciles were handled by collapsing the groups. The base-
line survival function was then re-calibrated if miscalibration was detected, by assigning an offset term to the 
LP in the Wales cohort. The re-calibrated baseline survival estimates were provided at 1-year time increments to 
ensure transparency of reporting and enable further research to utilise these models in predicting across shorter 
time horizons.
Utility in clinical decision making. Decision curve analysis was performed in external validation to 
assess the clinical utility of the models across clinically relevant threshold  probabilities37. We presented graphi-
cal summaries for the net benefit (benefit vs harm), where the model with the greatest net benefit has the most 
clinical value.
Presentation of final models for clinical use. The minimal resources risk model was converted into a 
risk score using Frank Harrell’s regression nomogram command in R, for ease of interpretation. The risk score 
was presented in both graphical and tabular form. The agreement between the LP estimates based on the mul-
tivariable Cox regression model and the LP estimates based on the points system was assessed using weighted 
(Equal-spacing and Fleiss-Cohen) Kappa, root mean square error (RMSE) and mean prediction error(MPE). 
Discrimination and calibration applying the points-based model on the external validation cohort was assessed 
using the c-statistic and calibration slope (supplemented with graphs), to assess the loss of information from 
simplifying the models into points.
Results
Baseline characteristics. Overall, 20,510 participants met our inclusion criteria in the derivation cohort 
(figure S1) and 13,346 in the Wales cohort (figure S2). Table 1 shows the baseline characteristics of participants at 
study entry in both London and Wales cohorts. The validation distribution of characteristics in the Wales cohort 
overlapped that of the London cohort and were on average comparable in many characteristics. They were on 
average four years older, with higher BMI, higher proportion of cardiovascular morbidity at baseline, with a 
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higher proportion of male participants, higher proportion with recently diagnosed diabetes and lower propor-
tion of Black ethnicity. The proportion of missing data overall and by missing in ACR (constituting the highest 
proportion missing, 50%) for the London cohort are provided in tables S2-S4. There were no marked differences 
in baseline demographic and clinical characteristics used in the models between missing and non-missing par-
ticipants, indicating low likelihood of violation of the missing at random assumption made in modelling.
Incidence of Stage 3 CKD. Incidence of Stage 3 CKD and mean follow-up times of participants are shown 
in Table S5. Over 5 years of follow-up, 1,378 individuals developed the outcome, corresponding to an incidence 
of 21.1 per 1000 person-years and stage 3 CKD probability of 0.094 (0.089–0.099) in the London cohort. In 
Wales, by 5-years 656 events were identified, corresponding to an incidence of 13.2(95% CI; 12.3–14.2) per 1000 
person-years and stage 3 CKD probability of 0.068 (0.062–0.073 ). Across all age groups, incidence rates in Wales 
were systematically lower than that of London, owing to the large proportion (11,474(86%)) of newly diagnosed 
diabetes cases at baseline in Wales.
Identified predictors. Table 2 shows the hazard ratios estimated using the three multivariable Cox regres-
sion models from the London cohort. Older age, Sex (male), longer duration of diabetes, higher HbA1c, lower 
HDL, hypertension, taking anti-hypertensive medication, taking insulin, CVD history, presence of STDR, albu-
minuria and lower eGFR were significantly associated with incident stage 3 CKD. Age was best modelled using a 
fractional polynomial term, as shown in Fig. 1 and therefore omitted from Table 2. There was a significant inter-
action found between age and insulin-use (Fig. 1; p < 0.001). The model coefficients remained largely unchanged 
Table 1.  Baseline characteristics of the study cohort. T2D type-2 diabetes; eGFR estimated glomerular 
filtration rate; Anti‑HT anti-hypertensive; CVD cardiovascular disease; HbA1c haemoglobin  A1c; STDR sight-
threatening diabetic retinopathy; BMI Body Mass Index; HDL High-density Lipoprotein; ACR Albumin: 
Creatinine ratio; IQR Interquartile range. ¥CVD includes Myocardial Infarction (MI), stroke, Atrial Fibrillation 
(AF), Heart failure (HF), Coronary Heart Disease (CHD) and Peripheral Vascular Disease (PVD).  ± Anti-
hypertensive agents include Angiotensin receptor blocker/Angiotensin-converting enzyme (ARB /ACE) drugs. 




Mean (±SD) or Median(IQR) or n (%)
Wales 
N=13,346 (events=656)
Mean (±SD) or Median(IQR) or n (%)
Age at baseline (Mean- years) 53.1 (12.7) 57.4(12.4)
Age at diagnosis of T2D (Mean-years) 49.7(12.2) 56.1(12.4)
Gender









(Mean SD– mm Hg) 131.5 (16.8) 136.7 (17.2)
Hypertension (antihypertensive use or 
SBP>130) 14,425 (70.3%) 10,778 (80.8%)
BMI‡
(Mean SD– kg/m2) 30.0 (6.1) 33.4 (7.1)
Duration of diabetes
Median IQR - years 0.0(0.0–5.6) 0.0 (0.0, 0.0)
Duration of diabetes (categorical), years
≥ 0 and<2.5












Yes 2,059 (10.0%) 2,281 (17.0%)
STDR 267 (1.3%) 198 (1.5%)
On insulin
Yes
1,441 (7.0% overall or 16.5% in prevalent 
diabetes cases)
242 (1.8% overall or 12.9% in prevalent 
diabetes cases)
On anti-HT agents ±
Yes 10,542 (51.4%) 7,721 (58.0%)
HbA1c
(Median IQR- mmol/mol) 58.5 (50.8–76.0) 56.0 (49.0, 76.0)
HDL-cholesterol
(Median IQR – mmol/L) 1.1 (1.0–1.3) 1.10 (0.90, 1.30)
ACR 
Median IQR – mg/mmol 1.0 (0.5–2.8) 0.90 (0.50, 2.10)
eGFR
(Median IQR- ml/min/1.73m2) 87.0 (76.0–90.0) 85.8 (76.0, 97.8)
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despite removing several variables from each of the simplified models. Sex was retained in all models as a con-
ceptual confounder for eGFR, despite p > 0.05.
Discrimination. Measures of discrimination and calibration were provided in Table 3. tenfold cross-vali-
dated Harrell’s C-statistic remained high with values ranging 0.852–0.853 in all models (Table 3). C-statistics 
remained high in external validation ranging 0.823–0.826 across models (Table 3).
Calibration slope. tenfold cross-validated calibration slopes measured by the beta coefficient of the LP were 
all near to 1 in internal validation. The calibration slope in external validation ranged 1.02–1.03 across the three 
models, showing on average an under-estimation of risk across all time points. The calibration plot (Fig. 2A) 
was generated after categorising the risks into 10 groups (with 2 groups collapsed due to inadequate number of 
events) which shows the models are over-predicting risks (O/E ratio ranged 0.799–0.810) at 5-years, particularly 
in the upper deciles of risk. Following model re-calibration, predicted risks were re-estimated using the recali-
brated survival estimate at 5-years in the Wales cohort (given in table S6). In Fig. 2B, the re-calibrated model 
suggests the predicted risks appear to be better aligned to the observed risks at 5-years, where the upper decile is 
on average over-predicting by 2% than what is observed. In comparison, the original minimal resources model 
over-estimates risk by more than 8%. Moreover, O/E ratios in the re-calibrated models are all near to 1 (Table 3).
Table 2.  Hazard ratios of selected risk factors for predicting 5-year risk of stage 3 CKD in all three resource-
driven models. T2D type-2 diabetes; eGFR estimated glomerular filtration rate; Anti‑HT anti-hypertensive; 
CVD cardiovascular disease; HbA1c haemoglobin  A1c; STDR sight-threatening diabetic retinopathy; BMI 
Body Mass Index; HDL High-density Lipoprotein; ACR Albumin: Creatinine ratio. Models included fractional 
polynomial terms for age and duration as follows: Age term was (age/10)^-0.5–0.43 (centered at age 54 years). 
Duration term was ln(duration + 0.003)/10 + 1.08. The models also included interaction terms between age 
and insulin-use for all three models, omitted from the table. The effect of the continuous predictor age by 
insulin-use is shown in Fig. 1 and the model equations presented in further detail in table S6. ¥CVD includes 
Myocardial Infarction (MI), stroke, Atrial Fibrillation (AF), Heart failure (HF) ,Coronary Heart Disease 
(CHD) and Peripheral Vascular Disease (PVD).  ± Anti-hypertensive agents include Angiotensin receptor 
blocker/Angiotensin-converting enzyme (ARB /ACE) drugs. † Compared to patients in the White, South Asian, 
Mixed or Other groups.
Confirmed eGFR < 60 mL/min per 1.73m2 (at two time points), stage 3 + code or dialysis
(N = 20,510; Events = 1378, total time at risk = 75,420.8 years)
Patient characteristic
Full model Reduced model Minimal-resources model























Black† 1.23 0.001 1.09–1.39 1.22 0.002 1.08–1.38 1.18 0.008 1.04–1.33
Duration of diabetes, years 1.05  < 0.001 1.04–1.07 1.05  < 0.001 1.04–1.07 1.05  < 0.001 1.04–1.07
eGFR , mL/min/1.73m2
 ≥ 60 and ≤ 70
 > 70 and ≤ 80





































































Systolic blood pressure, per 10 
unit increase in mmHg 1.05 0.003 1.02–1.08 1.05 0.004 1.01–1.09 1.05 0.003 1.02–1.08





















On AntiHT Agents ± 1.23 0.002 1.09–1.39 1.26  < 0.001 1.11–1.43 1.23 0.001 1.09–1.40
HbA1c, per 10 unit increase in 
mmol/mol 1.03 0.009 1.01–1.06 1.04 0.008 1.01–1.06 – – –
HDL, per 1 unit increase in 


















1.02–1.34 – – – – – –
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Risk groups. The mean(SD) LP shows the relatedness of the samples, these were presented in Table 3. For the 
validation cohort, we found an increased average LP and a decreased spread of the LP, consistent with deteriora-
tion of discriminative ability in the validation cohort.
The adjusted baseline survival estimates were computed from the derivation cohort and were combined with 
the LP to formulate risk equations (table S6). The survival rates in the three risk groups generated from 50 and 
84th centiles of prognostic index applying the minimal resources model are shown in Fig. 3 and labelled as low-
moderate risk, high-risk and very high-risk. Incidence rates in these groups were 1.2%, 8.7% and 35.6% respec-
tively (p < 0.001; log rank test) compared to an overall KM-rate of 9.4%. This shows how the models through 
Figure 1.  Fractional polynomial terms for age by use of insulin in derived minimal-resources risk model. 
Interaction effect between age and insulin use in the minimal-resources model, with age modelled as a fractional 
polynomial term. The y-axis shows the predicted 5-year risk holding all other covariates at the reference value.
Table 3.  Validation statistics for 5-year predicted risk of incident stage 3 CKD. LR likelihood-ratio test 
statistic; HR Hazard ratio; LP linear-predictor; O/E observed risk/estimated risk. Models were internally 
validated using tenfold cross validation. ¥ Group 1, 2 and 3 indicate participants grouped into the low-
moderate, high and very high-risk groups, respectively. ± For the points-based model categories were 
determined based on cox’s cut points from the minimal resources model. Moreover, the total score (adapted 
from coefficients of model 3) was fitted as a predictor on its own in a cox regression model for the validation, 
the reported statistics can be interpreted as measurements of performance.
Full model Reduced model Minimal-resources model Points-based model ± 
Internal  validation
London cohort (N = 20,510; 
events = 1378; total time at 
risk = 75,420.8 years)
Unadjusted (C-statistic) 0.855(0.846–0.864) 0.855(0.846–0.863) 0.853(0.845–0.862) 0.853(0.844–0.862)
tenfold cross-validated 
C-statistic (SD) 0.853 (SD 0.010) 0.853 (SD 0.010) 0.852 (SD 0.010) 0.852 (SD 0.016)
tenfold cross-validated 
calibration slope (SD) 0.988 (SD 0.043) 0.989 (SD 0.041) 0.990 (SD 0.044) 1.002 (SD 0.070)
LR 2568 2556 2539 2536
HR ¥:
Group 2 vs 1









LP (mean SD) 0.774 (SD 1.499) 0.771 (1.502) 0.808 (SD 1.487) 0.733 (SD 1.465)
External validation
Wales (N = 13,346; 
events = 656; total time at 
risk = 49,352.5 years)
C-statistic 0.827(SE 0.007) 0.826(SE 0.007) 0.824(SE 0.008) 0.823(SE 0.008)
Calibration slope 1.024(SE 0.035) 1.031(SE 0.035) 1.021(SE 0.035) 1.032(SE 0.036)
O/E 0.799 0.811 0.810 0.856
Re-calibrated O/E 0.994 0.992 0.995 1.056
LR 1000 996.7 979.9 976.6
HR ¥:
Group 2 vs 1









LP (mean SD) 0.875(SD 1.338) 0.862(SD 1.336) 0.889(SD 1.332) 0.818(SD 1.31)
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screening will enrich the proportion of positive predictive cases relative to not using this model. The hazard 
ratios between risk groups (Table 3) were reasonably well-maintained but larger in London for the high-risk 
group (London; 7.53(95% CI 5.97,9.50) vs Wales 5.50(95% CI 4.08,7.41)), meaning participants in the high-risk 
group in London develop stage 3 CKD at more than 7 times the rate per unit time compared to the low-risk 
group. Similarly, the hazard ratios appear larger in the London cohort for the very-high risk group (London; 
37.60 (95% CI 30.09, 46.99) vs Wales 25.25(95% CI 18.87,33.77), consistent with over-estimation seen in the 
calibration of the original models (Fig. 2A).
Sensitivity analyses. During the model development process, when taking ACR measurements within 
2  years before, or within 6  months after baseline, we increased our cohort by an additional 5,729 patients, 
who had missing ACR when the original 6-month criterion was applied. Previously non-significant covariates 
(from complete-case analysis of 20,510 samples) did not enter the models. There were no marked differences 
in multivariable hazard ratios or C-statistics for the models derived from sensitivity analysis to original models 
(table S7). Model discrimination and calibration of our final three models were assessed in key subgroups in the 
Wales cohort (table S8). C-statistics and calibration slopes appeared similar and did not differ greatly based on 
gender, duration of diabetes or age. The calibration slopes in sub-group analysis in all but females and partici-
pants above the age of 60 years, suggested an under-estimation of risks across all time-points. In participants 
60 years and over, model discrimination averaged 0.77(SE 0.01) across models and predictions were on average 
over-estimated (calibration slope < 1) across all time points. The calibration plot also indicated poorer calibration 
for predicting risk at 5-years, and over-estimation of risk was more apparent in the upper risk groups (figure S3), 
like the analysis on the total cohort. The models were better calibrated to females, across all time points (beta 
coefficient of calibration slope ranging 0.992–1.00) and at 5-years (figure S3). Following re-calibration of the 
baseline survival function, calibration plots in various subgroups show an improvement in the calibration slope 
Figure 2.  Calibration plots for derived models. Model predictions against observed event rates at 5-years 
given for 10 risk groups (collapsing first two groups due to inadequate event numbers in first two groups). 
Predictions from each decile were averaged, so these plots represent mean predicted risk against observed risks 
(KM-rates). (A) Represents 5-year calibration, baseline survival estimates from model development given as; 
0.9824, 0.9824, 0.9828 at 5-years for the three models respectively, were used to compute risks in this group. 
(B) Represents 5-year calibration plot- after recalibration, re-calibrated baseline survival estimates given as; 
0.9863,0.9860,0.9864 for full, reduced and minimal resources model respectively. Raw risk percentages provided 
below the plots for the minimal resources model.
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(figure S4). Moreover, following re-calibration observed rates of incident stage 3 CKD in the baseline eGFR cat-
egories were better aligned to the predicted risks (figure S5).
Clinical utility of models. Figures S6 presents the decision curves of our final models in terms of net ben-
efit in the external validation cohort. Model 3 that requires the least resources can stratify patients with an eGFR 
at baseline of at least 90 mL/min/1.73m2 to a range of predictions (0%-46%) at 5-years. There was negligible 
difference in the net benefit of our final models, suggesting that they have equal clinical value. At a threshold 
probability of 10% the minimal resources model in the Wales cohort identified 6.0 more cases per 100 patients 
without increasing the number treated unnecessarily and is equivalent to 54 fewer false positives per 100 patients 
compared to treating everyone.
Model presentation and recommended model. Predicted risks for the minimal-resources model 
were converted into “points” assigned to each predictor (table S9) and 5-year predicted risks (and re-calibrated 
risks) can be ascertained from table S10 after calculating the “total points”. The risk-score was supplemented with 
graphs presenting total points against predicted probabilities for both the original model and after recalibration 
(figure S7). Alternatively, the total points can be mapped onto the LP using the following linear transformation: 
LP =  − 4.34 + 0.05*Total points, which can be used to compute the stage 3 CKD probability. Due to the loss of 
information from using a points-based system with values of the continuous predictors and points presented to 
the nearest integer, we assessed the degree of agreement between these two methods. Table S11 illustrates the 
agreement between 5-year risk estimates produced by the nomogram (points) and those based on evaluating 
the cox model directly, yielding excellent agreement with minimal loss of information from simplifying models 
into a risk score (Equal-spacing kappa (κ) = 0.958 (ASE 0.001), Fleiss-Cohen kappa (κ) = 0.976 (ASE 0.001), 
RMSE = 0.039, MPE = -0.953). The points-based system was evaluated in the Wales cohort and had similar dis-
crimination and calibration compared to the original models (C-statistic; 0.823,SE 0.008 and calibration slope; 
1.032,SE 0.036). The calibration slope at 5-years show a similar calibration and re-calibration profile to that of the 
estimates based on evaluating cox model directly (figure S8). We would therefore recommend the points-based 
minimal resources model for global use.
Discussion
In this study we developed 3 (resource-driven) risk models for predicting the onset of stage 3 CKD in multi-
ethnic persons with T2D within an economically and socially deprived region of inner London. All models were 
rigorously internally validated using tenfold cross-validation re-sampling38,39 achieving excellent discrimination 
and when externally validated to a cohort of participants in Wales of predominantly white ethnicity. The models 
were successfully updated to generalise over datasets covering Wales as a population with a lower incidence of 
stage 3 CKD. Eliminating variables such as HbA1c, HDL, history of CVD and presence of STDR, led to negli-
gible differences in model performance of the three models. These new prediction equations therefore could be 
applied to screen diabetes-related CKD to help target prevention strategies accurately in resource-constrained 
environments.
Table S1 shows the currently available risk models for identifying Stage 3 CKD, defined by reduced eGFR to 
60 ml/min/1.73m2. Our models differ from these recent prognostic modelling equations. The Risk Equations 
Figure 3.  Kaplan–Meier curves stratified by risk groups according to model predictions. This figure shows 
observed probabilities over time in the derivation and validation datasets by risk group according to predictions 
from the minimal resources model. The prognostic groups were defined by categorising the linear predictor 
according to the cut-points representing the 50th and 84th centiles, equivalent to LP(linear predictor) values 
of: ≤ 0.72, > 0.72 and ≤ 2.36, > 2.36 or predicted risks of ≤ 3.6%, > 3.6% and ≤ 17.2%, > 17.2%.
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for Complications Of type 2 Diabetes(RECODe) study equations for CKD, developed using 9,635 Action to 
Control Cardiovascular Risk in Diabetes(ACCORD) study participants, achieved good discrimination and vari-
able  calibration40. A variety of equations were developed to assess different endpoints for CKD in this study, all 
of which included 5–6 (costly) laboratory tests or examinations that require the presence of a trained profes-
sional. Therefore, implementing these in regions with basic laboratory facilities is not practical. Our models 
have reduced the number of laboratory tests to a maximum of 2 tests that are widely available and eliminated 
the need for determining the history of CVD or screening for STDR, which are usually not obtainable in LMICs. 
The risk model by O’Seaghdha41 consisted of the least number of resources (eGFR, ACR, diabetes, hypertension 
and age), developed using data from the Framingham heart study (FHS) and previously externally validated in 
1777 participants from the Atherosclerosis Risk in communities(ARIC) Study (C-statistic; 0.79 in Framingham, 
0.74 in ARIC). O’Seaghdha et al. presented an even simpler model, however it did not have eGFR or urine ACR 
which are known clinically important variables used to guide treatment decisions for  CKD4,42,43. Furthermore, 
participants from FHS were 100% white and 76% white in the ARIC study. Such equations would have poorer 
transportability to LMICs or ethnically diverse populations, whereas ours has been shown to validate well in 
ethnically homogenous (Wales) and heterogenous populations (inner London).
The risk equations by Nelson et al.44 developed on 34 multinational cohorts from the CKD Prognosis Con-
sortium, predicts incident eGFR < 60 mL/min/1.73m2 with excellent discrimination but again the final study 
equation required 5 laboratory/examination variables.
A study by Jardine et al.45, conducted on 11,140 T2D participants from the Action in Diabetes and Vascular 
Disease(ADVANCE) trial shows eGFR and urine ACR to be the leading predictors for predicting stage 3 CKD 
and when taken together yield a similar c-statistic(95% CI) to ours (0.818(0.781–0.855)). Their final risk pre-
diction model which incorporated 7 risk factors produced a C-statistic(95% CI) of 0.847 (0.815–0.880). While 
model discriminatory power was high and model variables kept to a minimum, the study participants recruited 
were a select group with high vascular risk and therefore may not generalise to an unbiased population of people 
with T2D.
The strengths of our study are that we ensured applicability of these risk tools to routine clinical care in LMIC 
by developing resource-based models. Derivation of our models was based on a large sample, achieving adequate 
statistical power. Furthermore, the average differences between our cohorts reflect that this is a more challenging 
external validation of a model. This is an advantage in validation research as these models with good external 
performance tend to substantiate the transportability of the models over  reproducibility46. Decision curve analy-
sis revealed negligible differences in terms of net benefit for our final three models. These economically viable 
risk models have near equal clinical utility, warranting the removal of several commonly used tests in CKD risk 
models and allowing for more accessible risk equations for use in poorly resourced communities. Furthermore, 
we have converted a complex statistical model derived from FP functions and interactions into a simple risk 
score, showing excellent agreement with predictions from direct evaluation of the cox model. Therefore, our 
most resource-minimal model can be easily applied in routine clinical care for decision support.
However, there were several limitations. Firstly, due to the study design and gradual decline in renal function 
in mostly asymptomatic persons with diabetes, the exact date of onset of Stage 3 CKD is difficult to pinpoint and 
so underestimation of the incidence of Stage 3 CKD cannot be ruled  out47. However, people with T2D undergo 
regular blood tests unlike people in the general population, and so likelihood of miss-classification bias would 
be low. Secondly, although discrimination was maintained throughout the models, initial attempts to validate in 
Wales prior to recalibration show the calibration at 5-years were suboptimal. O/E ratios were below 1, suggest-
ing that the models were over-fitted to the developmental dataset. The predictive performance was improved 
following recalibration of the baseline survival function, as incidence rates were generally lower in the Wales 
cohort. Thirdly, risk equations may be redundant if primary care practices do not encourage regular testing for 
albuminuria, where missing data in ACR was particularly high in both London (50%) and Wales (49%) cohorts. 
We stress that for identifying incident stage 3 CKD, it would be improper to advocate diabetes risk models 
without albuminuria or  eGFR4,42,43. Finally, external validation in LMIC’s and in other clinically relevant sub 
populations is encouraged to ensure transportability and generalisability of the risk models. This is currently 
challenging due to the lack of quality primary care data in LMICs.
In conclusion, we have developed and validated three resource driven models in T2D that may be applied 
globally to predict incident Stage 3 CKD. Our models can be applied for population screening using the least 
number of costly variables, enabling more efficient detection of people who require urgent prevention strategies. 
In resource constrained environments we would favour use of the minimal-resources model presented as a risk 
score, conserving most of the predictive information and consisting of the least number of variables. However, 
further external validation is recommended especially for utilisation in pragmatic prevention trials on CKD.
Data availability
The primary output of this study are the risk models and the equations are in the manuscript. The data used for 
the study is third-party data: it is held by Queen Mary’s University London (QUML) and the SAIL Databank at 
Swansea University on behalf of health care providers in Inner London and Wales who are the original data own-
ers respectively. The permission to access fully anonymised previously curated data from QUML was obtained 
from the Caldicott guardian and data from SAIL is available to anyone via an application to SAIL.
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